Access Dermatology

Breaking News

• Breaking News List »
• breaking_news_2008 »
• 09 »

A randomized, double-blind, controlled study of a calcipotriene and betamethasone combination versus the individual components in scalp psoriasis

A 4-arm, 8-week, multicenter, randomized, double-blind, vehicle-controlled study in 1505 patients with scalp psoriasis was conducted. The treatments comprised calcipotriene and betamethasone dipropionate (50 ug/kg and 0.5 mg/g, respectively); betamethasone dipropionate (0.5 mg/g) in the same vehicle; calcipotriene (50 ug/kg) in the same vehicle and vehicle alone. Patients achieving "absent" or "very mild" disease grades at week 8 were 71.2%, 64%, 36.8% and 22.8% in the combination, betamethasone, calcipotriene and vehicle groups, respectively. All the treatments were significantly different from the vehicle group. Thus co-therapy with calcipotriene and betamethasone was superior to either component alone or to vehicle (Jemec, G.B.E. et al. J Am Acad Dermatol 2008, 59[3]: 455-463). --> -->